Irina N. Serebryakova
Irina N. Serebryakova has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Nikolay Nikolayevich Tupitsyn
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
4 shared publications - Aleksandr V. Popa
The Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation
3 shared publications - Alexandra Dmitrievna Palladina
Research Institute of Clinical Oncology, the N.N. Blokhin National Medical Research Center of Oncology of Ministry of Healthcare of the Russian Federation
3 shared publications - Meri A. Shervashidze
LA Durnov Research Institute of Pediatric Oncology and Hematology, NN Blokhin National Medical Cancer Research Center, 23 Kashirskoye sh., Moscow, Russian Federation, 115522
2 shared publications - Natalia Alexandrovna Kupryshina
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
2 shared publications - Olga Chernysheva
Blokhin National Medical Research Center of Oncology
2 shared publications
Latest Publications
- Open Access
- 26 March 2025
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 24 (1) , 39-49
The role of epigenetic therapy in the treatment of childhood acute myeloid leukemia
The treatment results of children with acute myeloid leukemia (AML) still remain unsatisfactory. The standard chemotherapy allows achieving complete remission in 91–96% of patients, but the event-free (EFS) and overall (OS) survival rates are still not high enough, the main cause of treatment failure in children with AML is relapse of the disease. DNA methylation and histone modification are major epigenetic changes in AML, leading to silencing of tumor suppressor genes. Research of the epigenetic control of gene expression in AML through histone modification and DNA demethylation promotes better understanding of the biology of blasts.The aim of our study: to prove the effectiveness of the NII DOG AML 2012 protocol based on the combination of standard chemotherapy and epigenetic therapy. The study was approved by the Independent Ethics Committee and the Scientific Council of the N.N. Blokhin NMRC of Oncology of Ministry of Healthcare of the Russian Federation. From 01.01.2013 to 31.05.2019, the following patients were enrolled in the study: 35 patients who were receiving treatment according to the NII DOG AML 2012 protocol and 52 patients who were receiving treatment according to the AML-BFM 2004 protocol. Between two groups, there was no significant difference in sex, age, and distribution by risk groups. The high-risk and intermediate-risk patients received 5 courses of chemotherapy (AIE, HAM, AI, hAM, HAE) and the standard-risk patients received 4 courses of chemotherapy (AIE, AI, hAM, HAE). Epigenetic therapy according to the NII DOG AML 2012 protocol consisted of valproic acid (weeks 1–78), all-trans-retinoic acid (days 1–43 and then days 1–14 of each subsequent chemotherapy course) and decitabine 20 mg/m2 which was given within a therapeutic window in 5 patients and 26 patients received it on days 16–20 from the beginning of treatment. Six patients received 5-azacitidine instead of decitabine. There was no toxicity in 5 patients who received decitabine within a therapeutic window: one patient developed relapse (13 months) and one patient died of severe infection after induction therapy on day 17, three patients are still alive in complete remission (67, 70, and 72 months), with two of them having received haploidentical hematopoietic stem cell transplantation. All the patients who received decitabine on days 16–20 achieved complete remission after induction therapy (2 patients of them did not respond to AIE treatment and achieved remission only after decitabine treatment). Among the patients who were treated with chemotherapy only, complete remission was achieved in 82.6% (p = 0.04). In the patients treated according to the NII DOG AML 2012 protocol, the 5-year EFS and OS was 69.1 ± 9.8%, and 73.5 ± 9.4%, respectively, vs 54.0 ± 7.3% (p = 0.2) and 69.2 ± 6.4% (p = 0.58) in the patients treated with chemotherapy only. The five-year EFS and cumulative incidence of relapse (CIR) of the high-risk patients treated according to the NII DOG AML 2012 and AML-BFM 2004 protocol were 77.8 ± 13.4% vs 50.0 ± 8.6% (p = 0.044) and 15.2 ± 10% vs 42.5 ± 9.2% (p = 0.056), respectively. None of the patients treated according to the NII DOG AML 2012 protocol underwent allogeneic hematopoietic stem cell transplantation (HSCT) during the first remission. After excluding from the analysis 6 patients who received allogeneic HSCT during the first remission and were treated according to the AML-BFM 2004 protocol, the EFS and CIR rates of the high-risk patients were 46.4 ± 9.4% (p = 0.02) and 47.4 ± 9.5% (p = 0.029), respectively. All the six patients who received 5-azacitidine instead of decitabine died (one patient died during induction therapy and 5 patients died of AML progression) and further study of this arm of the protocol was closed. Thus, the addition of epigenetic therapy to standard chemotherapy in pediatric patients with AML reduced the CIR, increased the number of complete remissions and the overall survival compared with the patients treated with chemotherapy only. The high-risk patients treated according to the NII DOG AML 2012 protocol achieved higher EFS and lower CIR rates compared with the patients who received no demethylating agents and underwent no allogeneic HSCT. Probably, epigenetic therapy may allow patients to avoid allogeneic HSCT during the first complete remission. According to our study results, decitabine has shown to be more effective than 5-azacitidine. Decitabine should be given after the first course of induction therapy during the period of aplasia.
- 26 March 2025
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 24 (1) , 39-49
Open AccessThe role of epigenetic therapy in the treatment of childhood acute myeloid leukemia
The treatment results of children with acute myeloid leukemia (AML) still remain unsatisfactory. The standard chemotherapy allows achieving complete remission in 91–96% of patients, but the event-free (EFS) and overall (OS) survival rates are still not high enough, the main cause of treatment failure in children with AML is relapse of the disease. DNA methylation and histone modification are major epigenetic changes in AML, leading to silencing of tumor suppressor genes. Research of the epigenetic control of gene expression in AML through histone modification and DNA demethylation promotes better understanding of the biology of blasts.The aim of our study: to prove the effectiveness of the NII DOG AML 2012 protocol based on the combination of standard chemotherapy and epigenetic therapy. The study was approved by the Independent Ethics Committee and the Scientific Council of the N.N. Blokhin NMRC of Oncology of Ministry of Healthcare of the Russian Federation. From 01.01.2013 to 31.05.2019, the following patients were enrolled in the study: 35 patients who were receiving treatment according to the NII DOG AML 2012 protocol and 52 patients who were receiving treatment according to the AML-BFM 2004 protocol. Between two groups, there was no significant difference in sex, age, and distribution by risk groups. The high-risk and intermediate-risk patients received 5 courses of chemotherapy (AIE, HAM, AI, hAM, HAE) and the standard-risk patients received 4 courses of chemotherapy (AIE, AI, hAM, HAE). Epigenetic therapy according to the NII DOG AML 2012 protocol consisted of valproic acid (weeks 1–78), all-trans-retinoic acid (days 1–43 and then days 1–14 of each subsequent chemotherapy course) and decitabine 20 mg/m2 which was given within a therapeutic window in 5 patients and 26 patients received it on days 16–20 from the beginning of treatment. Six patients received 5-azacitidine instead of decitabine. There was no toxicity in 5 patients who received decitabine within a therapeutic window: one patient developed relapse (13 months) and one patient died of severe infection after induction therapy on day 17, three patients are still alive in complete remission (67, 70, and 72 months), with two of them having received haploidentical hematopoietic stem cell transplantation. All the patients who received decitabine on days 16–20 achieved complete remission after induction therapy (2 patients of them did not respond to AIE treatment and achieved remission only after decitabine treatment). Among the patients who were treated with chemotherapy only, complete remission was achieved in 82.6% (p = 0.04). In the patients treated according to the NII DOG AML 2012 protocol, the 5-year EFS and OS was 69.1 ± 9.8%, and 73.5 ± 9.4%, respectively, vs 54.0 ± 7.3% (p = 0.2) and 69.2 ± 6.4% (p = 0.58) in the patients treated with chemotherapy only. The five-year EFS and cumulative incidence of relapse (CIR) of the high-risk patients treated according to the NII DOG AML 2012 and AML-BFM 2004 protocol were 77.8 ± 13.4% vs 50.0 ± 8.6% (p = 0.044) and 15.2 ± 10% vs 42.5 ± 9.2% (p = 0.056), respectively. None of the patients treated according to the NII DOG AML 2012 protocol underwent allogeneic hematopoietic stem cell transplantation (HSCT) during the first remission. After excluding from the analysis 6 patients who received allogeneic HSCT during the first remission and were treated according to the AML-BFM 2004 protocol, the EFS and CIR rates of the high-risk patients were 46.4 ± 9.4% (p = 0.02) and 47.4 ± 9.5% (p = 0.029), respectively. All the six patients who received 5-azacitidine instead of decitabine died (one patient died during induction therapy and 5 patients died of AML progression) and further study of this arm of the protocol was closed. Thus, the addition of epigenetic therapy to standard chemotherapy in pediatric patients with AML reduced the CIR, increased the number of complete remissions and the overall survival compared with the patients treated with chemotherapy only. The high-risk patients treated according to the NII DOG AML 2012 protocol achieved higher EFS and lower CIR rates compared with the patients who received no demethylating agents and underwent no allogeneic HSCT. Probably, epigenetic therapy may allow patients to avoid allogeneic HSCT during the first complete remission. According to our study results, decitabine has shown to be more effective than 5-azacitidine. Decitabine should be given after the first course of induction therapy during the period of aplasia.
- Open Access
- 19 May 2021
- Published by Consilium Medicum in Journal of Modern Oncology
- Vol. 23 (1) , 148-155
Detection and monitoring of minimal residual disease in acute megakaryoblastic leukemia in children
Acute megakaryoblastic leukemia (AMKL) is a rare subtype of acute myeloid leukemia (AML), which is associated with poor prognosis for all patients except children with t(1;22) or Down syndrome. The frequency of complete remission in case of AMKL is comparable to the frequency of complete remission in other variants of AML, and the median survival is much lower. This determines the necessity to update criteria for assessment of the effect of treatment using flow cytometry definition of the level of minimal residual disease (MRD). Nowadays, there are no unified and standardized approaches for the measurement of MRD in case of myeloid leukemia, including AMKL, which prohibits adequate assessment of the therapy effect and in some cases determination of the indications for allogeneic hematopoietic stem cells transplantation. The article identifies diagnostic features and describes approaches for the measurement of the level of MRD in case of AMKL. Aim. The aim is to demonstrate the algorithms for diagnosing and measuring MRD in case of AML-M7 in children. Materials and methods. The article analyzes the clinical and immunological profile of 10 boys and 4 girls with the initial diagnosis of AMKL between the ages of 3 months 12 years old, 13 of them have received treatment in the FSBI N.N. Blokhin National Medical Research Center of Oncology and one in the GBUZ Morozovsky DGKB between 1995 and 2020, The measurement of MRD was carried out in 6 patients. The measurement of MRD was carried out using both morphocytochemical method and multiparameter flow cytometry with megakaryocyte markers (CD61, CD42, CD41) in combination with other myeloid markers (CD13, CD33), CD34, CD117 and aberrant markers (mainly CD7). Results. We showed that adequate measurement of the level of MRD had required detailed immunophenotyping during diagnosis to determine the aberration of megakaryoblasts. CD9 marker (100%), CD33 myeloid marker (69.2%), stem cell antigen CD34 (46.2%), CD13 (38.2%) in addition to megakaryocyte markers (100%) were most often expressed on blast cells in case of AMKL. The CD117 antigen was present on the blasts in 33.3% of cases. The expression of the T-cell-associated CD7 antigen (46.2%) was frequent. The measurement of MRD was carried out during the treatment (usually after an induction course) on the basis of the markers of megakaryocytic cell line (CD61, CD41, CD42a, CD42b), weak CD45 expression, as well as the immunophenotype characteristics during initial diagnosis. The level of MRD ranged from completely negative (0%; 0.006%) to evident (1.05%). Conclusion. The detection of residual tumor megakaryoblasts in case of AML-M7 using flow cytometry is a promising method to evaluate the effect of therapy. The adequate measurement of the level of MRD requires detailed immunophenotyping during the diagnosis to determine the aberration of megakaryoblasts.
- 19 May 2021
- Published by Consilium Medicum in Journal of Modern Oncology
- Vol. 23 (1) , 148-155
Open AccessDetection and monitoring of minimal residual disease in acute megakaryoblastic leukemia in children
Acute megakaryoblastic leukemia (AMKL) is a rare subtype of acute myeloid leukemia (AML), which is associated with poor prognosis for all patients except children with t(1;22) or Down syndrome. The frequency of complete remission in case of AMKL is comparable to the frequency of complete remission in other variants of AML, and the median survival is much lower. This determines the necessity to update criteria for assessment of the effect of treatment using flow cytometry definition of the level of minimal residual disease (MRD). Nowadays, there are no unified and standardized approaches for the measurement of MRD in case of myeloid leukemia, including AMKL, which prohibits adequate assessment of the therapy effect and in some cases determination of the indications for allogeneic hematopoietic stem cells transplantation. The article identifies diagnostic features and describes approaches for the measurement of the level of MRD in case of AMKL. Aim. The aim is to demonstrate the algorithms for diagnosing and measuring MRD in case of AML-M7 in children. Materials and methods. The article analyzes the clinical and immunological profile of 10 boys and 4 girls with the initial diagnosis of AMKL between the ages of 3 months 12 years old, 13 of them have received treatment in the FSBI N.N. Blokhin National Medical Research Center of Oncology and one in the GBUZ Morozovsky DGKB between 1995 and 2020, The measurement of MRD was carried out in 6 patients. The measurement of MRD was carried out using both morphocytochemical method and multiparameter flow cytometry with megakaryocyte markers (CD61, CD42, CD41) in combination with other myeloid markers (CD13, CD33), CD34, CD117 and aberrant markers (mainly CD7). Results. We showed that adequate measurement of the level of MRD had required detailed immunophenotyping during diagnosis to determine the aberration of megakaryoblasts. CD9 marker (100%), CD33 myeloid marker (69.2%), stem cell antigen CD34 (46.2%), CD13 (38.2%) in addition to megakaryocyte markers (100%) were most often expressed on blast cells in case of AMKL. The CD117 antigen was present on the blasts in 33.3% of cases. The expression of the T-cell-associated CD7 antigen (46.2%) was frequent. The measurement of MRD was carried out during the treatment (usually after an induction course) on the basis of the markers of megakaryocytic cell line (CD61, CD41, CD42a, CD42b), weak CD45 expression, as well as the immunophenotype characteristics during initial diagnosis. The level of MRD ranged from completely negative (0%; 0.006%) to evident (1.05%). Conclusion. The detection of residual tumor megakaryoblasts in case of AML-M7 using flow cytometry is a promising method to evaluate the effect of therapy. The adequate measurement of the level of MRD requires detailed immunophenotyping during the diagnosis to determine the aberration of megakaryoblasts.
- Open Access
- 8 December 2020
- Published by Publishing House ABV Press in Russian Journal of Biotherapy
- Vol. 19 (4) , 45-53
RELATIONSHIP OF BLAST CELL IMMUNOPHENOTYPE WITH REMISSION IN ACUTE MYELOID LEUKEMIA IN CHILDREN
Introduction. Acute myeloid leukemia (AML) is a clonal disease of the blood system that occurs as a result of mutations in the genome of hematopoietic progenitor cells. As a result of mutations, the linear differentiation of hematopoietic cells is replaced by the proliferation of malignant myeloid progenitors. Currently, the risk group for AML in children is determined mainly by the presence of specific gene and chromosomal abnormalities and an increased level of peripheral blood leukocytes. The features of the immunophenotype of blast cells can also influence the course of the disease.The aim of the work is to assess the relationship between the immunophenotypic parameters of blast cells and the probability of achieving remission in children with AML.Materials and methods. The study included 109 patients aged 3 months to 17 years who received treatment according to the AML BFM 87, AML BFM 2004, NII DOG AML 2007 и NII DOG AML 2012 protocol in the period from 1991 to 2020.Results. The study showed the relationship between the probability of achieving remission and the presence of markers CD33, CD19 and CD14 on tumor cells. Expression of lymphoid antigen CD19 on blasts was associated with a higher rate of remission (73.0 % vs 95.5 %, p = 0.027). The absence of the linearly associated myeloid marker CD33 negatively correlated with the remission rate (61.1 % vs 87.7 %, p = 0.007). In the presence of monocyte antigen CD14 on blasts, the probability of achieving remission was low (95 % vs 50 %, p = 0.013).Conclusion. Characteristics of the immunophenotype of tumor cells in AML in children are associated with the probability of achieving remission.
- 8 December 2020
- Published by Publishing House ABV Press in Russian Journal of Biotherapy
- Vol. 19 (4) , 45-53
Open AccessRELATIONSHIP OF BLAST CELL IMMUNOPHENOTYPE WITH REMISSION IN ACUTE MYELOID LEUKEMIA IN CHILDREN
Introduction. Acute myeloid leukemia (AML) is a clonal disease of the blood system that occurs as a result of mutations in the genome of hematopoietic progenitor cells. As a result of mutations, the linear differentiation of hematopoietic cells is replaced by the proliferation of malignant myeloid progenitors. Currently, the risk group for AML in children is determined mainly by the presence of specific gene and chromosomal abnormalities and an increased level of peripheral blood leukocytes. The features of the immunophenotype of blast cells can also influence the course of the disease.The aim of the work is to assess the relationship between the immunophenotypic parameters of blast cells and the probability of achieving remission in children with AML.Materials and methods. The study included 109 patients aged 3 months to 17 years who received treatment according to the AML BFM 87, AML BFM 2004, NII DOG AML 2007 и NII DOG AML 2012 protocol in the period from 1991 to 2020.Results. The study showed the relationship between the probability of achieving remission and the presence of markers CD33, CD19 and CD14 on tumor cells. Expression of lymphoid antigen CD19 on blasts was associated with a higher rate of remission (73.0 % vs 95.5 %, p = 0.027). The absence of the linearly associated myeloid marker CD33 negatively correlated with the remission rate (61.1 % vs 87.7 %, p = 0.007). In the presence of monocyte antigen CD14 on blasts, the probability of achieving remission was low (95 % vs 50 %, p = 0.013).Conclusion. Characteristics of the immunophenotype of tumor cells in AML in children are associated with the probability of achieving remission.
- Open Access
- 31 December 2019
- Published by Consilium Medicum in Journal of Modern Oncology
- Vol. 21 (4) , 22-26
Modern immunological criteria for a stratification of risk groups for precursor B cell acute lymphoblastic leukemia in children
Background. Modern therapy programs allow achieving high survival rates in children with acute lymphoblastic leukemia (ALL). However, there is a group of patients in whom a relapse occurs, which makes it necessary to search for optimal tools for monitoring remission and the earliest detection of ALL relapse. According to clinical and immunological studies, assessment of minimal residual disease (MRD) levels is one of the leading criteria for response to treatment and can be the basis for risk-stratified therapy. Aim. Assessment of MRD levels on the 15th day of induction as the main parameter for stratification of patients into prognostic risk groups and the impact of MOB levels on patient survival. Materials and methods. The study included 117 children with a newly diagnosed precursor B-cell ALL. All patients were given an induction course according to the BFM ALL IC 2009 protocol. MRD levels were determined by flow cytometry. Results. Given the MRD based stratification, a truly standard risk group was identified, the survival rate of which reached 100%. Conclusions. The use of MRD as the main tool for the risk of adapted therapy made it possible to improve survival in patients of the standard risk group, as well as to optimize therapy for high and medium risk groups in the future.
- 31 December 2019
- Published by Consilium Medicum in Journal of Modern Oncology
- Vol. 21 (4) , 22-26
Open AccessModern immunological criteria for a stratification of risk groups for precursor B cell acute lymphoblastic leukemia in children
Background. Modern therapy programs allow achieving high survival rates in children with acute lymphoblastic leukemia (ALL). However, there is a group of patients in whom a relapse occurs, which makes it necessary to search for optimal tools for monitoring remission and the earliest detection of ALL relapse. According to clinical and immunological studies, assessment of minimal residual disease (MRD) levels is one of the leading criteria for response to treatment and can be the basis for risk-stratified therapy. Aim. Assessment of MRD levels on the 15th day of induction as the main parameter for stratification of patients into prognostic risk groups and the impact of MOB levels on patient survival. Materials and methods. The study included 117 children with a newly diagnosed precursor B-cell ALL. All patients were given an induction course according to the BFM ALL IC 2009 protocol. MRD levels were determined by flow cytometry. Results. Given the MRD based stratification, a truly standard risk group was identified, the survival rate of which reached 100%. Conclusions. The use of MRD as the main tool for the risk of adapted therapy made it possible to improve survival in patients of the standard risk group, as well as to optimize therapy for high and medium risk groups in the future.